Reliance Life Sciences has received approval from the USFDA for its active pharmaceutical ingredient (API) manufacturing facility located at Dhirubhai Ambani Life Sciences Centre in Navi Mumbai. The company manufactures cytotoxic APIs used to make drugs for the treatment of cancer. The inspection of the facility was carried out by US FDA investigators in August 2015. The approval covers two of the later-generation oncology molecules, temozolomide and pemetrexed. Temozolomide is used for the treatment of glioblastoma multiforme, a type of brain tumor. Pemetrexed is used for the treatment of non-small cell lung cancer.
Company Profile : Reliance Life Science Ltd
Leave a Reply